Julita, California – (Benus Wayer/”Etos Wire”) – Today's “Lanojin” company (listed on the Nasdaq Stock Exchange: ingn), a medical technology company that provides innovative respiratory products for use in home care facilities, today announced that it has entered into strategic cooperation with Jiangsu Yuo medical (Tase 🙂 Equipment & Supply Co., Ltd. (002223.sz, Yuwell), Global Company for the Manufacture of Medical Home Health Care with a comprehensive set of respiratory products.
Strategic cooperation is expected to expand the Inogen (NASDAQ products 🙂 by distributing some respiratory products in the United States and choosing other regions, expanding and strengthening the Inogen innovation line through cooperation in the field of research and development, and accelerating the entry of the Inogen brand To the market. Chinese market. In addition, Yuweell, through its subsidiary, agreed to invest nearly 27.2 million US dollars in Inogen, which represents 9.9% of joint shares, which enhances cooperation and enhances the public budget of Inogen.
Cooperation with Yuwell is a pivotal step in accelerating the Inogen growth path. “By expanding the portfolio of our products and our global presence and enhancing our innovation line, we expect to be in a good position that allows us to seize new opportunities in the market,” said Kevin Smith, President and CEO. This cooperation supports our commitment to providing long -term value to our shareholders and enhances our vision of creating inogen as a platform for the best respiratory solutions for patients all over the world. We are confident that our cooperation with Yuwell will play a decisive role in our continuous success. “
Alex Wu, Chairman of Yuwell, added that Inogen is a leading company in the respiratory treatment market, and our strategic cooperation provides both parties to expand their geographical access and meet patients' needs all over the world. Yuwell shares Inogen's commitment to developing and providing innovative and high -quality products, and we believe that together we can make a tangible difference in the lives of respiratory patients. Yuweell and Inogen aims to determine the next generation of respiratory products.
The cooperation agreement will be effective immediately, while the purchase of shares from Inogen is expected to be closed during the first quarter of 2025, taking into account some conditions of customary closure.
About enolujin
Inogen (Nasdaq: ingn) is a leading global medical technology company that provides innovative respiratory products for use in the home care environment. Inogen supports patient respiratory care through the development, manufacture and marketing of innovative respiratory devices in their category used to provide care for patients with chronic respiratory diseases. Inogen cooperates with patients, prescriptions, home medical equipment providers and distributors to make respiratory treatment products widely available, giving patients the opportunity to manage the effect of their disease.
For more information, please visit www.inogen.com.
Inogen used and intends to continue to use its investor relationship, http://investor.inogen.com/, as a way to detect non -general material information and to comply with its disclosure obligations under the FD regulation.
About Uwalel
Since its foundation in 1998, Yuweell has been at the forefront of companies that provide advanced medical devices solutions to enhance patient care and improve home health care around the world. Yuwell (002223.sz) achieved revenues of more than one billion US dollars in 2023, and it has a range of wide products that include respiratory treatment, diabetes management, electronic diagnostic products, first aid and rehabilitation solutions, among other areas.
Thanks to its fixed commitment to clinical excellence, Yuwell offers high -quality and medically reliable products that can achieve superior results for patients.
Through 9 advanced research and development centers and 7 advanced production facilities, the global Yuwell presence in more than 100 countries extends and supports more than 300,000 health care institutions. Yuwell affects the lives of patients all over the world by bringing in professional and easy -to -use medical devices to the home.
Approcessing data
This press statement contains aspecting data in the meaning intended in the 1995 litigation reform law. All the data contained in this statement are not historical facts, including, but not limited to, data related to future INOGEN business plans and market opportunities. Financial expectations. And growth strategies and expected operational results are aspiration. Words such as goals, believe, expect, plan, expect, will, intend, potential, possible, and similar expressions to determine aspiration data. The aspiration data is subject to many risks and doubts that may cause actual results materially from the current expected results, including but not limited to, the risks and doubts related to the potential benefits of Inogen cooperation with Yuwell; Complete the conditions of closure under the Financial Power purchase agreement related to investment in stocks; The timing of closing investment in stocks; The market acceptance of its products; a race; And its capabilities in the field of sales, marketing and distribution; Sales, marketing, research and planned development activities; And the risks associated with international operations. To obtain a detailed discussion of these risks and other risks that can affect Inogen and their financial performance, please refer to the danger factors section in its annual report according to the 10-K model for the period ending December 31, 2023, and its quarterly report according to the 10-K model. Q for the calendar quarter ended on March 31, 2024 and in its other files with the Securities and Exchange Committee. This aspiration data speaks only from its history. Inogen disavows any commitment to updating these aspiration data except for what is required by the law.
Display the source version on Businesswire.com: https://www.businingwire.com/news/home/20250126900450/en/
Ir@inogen.net
Source: Enogen Company
